Provided by Tiger Trade Technology Pte. Ltd.

Absci Corporation.

3.39
-0.1600-4.51%
Post-market: 3.400.0100+0.29%17:36 EST
Volume:2.81M
Turnover:9.78M
Market Cap:509.76M
PE:-3.78
High:3.64
Open:3.57
Low:3.36
Close:3.55
52wk High:6.33
52wk Low:2.01
Shares:150.37M
Float Shares:127.00M
Volume Ratio:0.64
T/O Rate:2.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8966
EPS(LYR):-0.9353
ROE:-55.68%
ROA:-30.62%
PB:2.42
PE(LYR):-3.62

Loading ...

Absci Corporation Announces Launch of Clinical Trials for AI-Designed Therapeutic ABS-201 Targeting Androgenetic Alopecia

Reuters
·
Aug 26

Press Release: Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg

Dow Jones
·
Aug 26

Absci Corporation to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Reuters
·
Aug 20

Absci Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 18

Absci Corp: Sales Agreement Prospectus Covering Offering of up to $100 Mln of Common Stock That May Be Issued From Time to Time

THOMSON REUTERS
·
Aug 13

Absci Corp Files for Mixed Shelf of up to $400 Mln – SEC Filing

THOMSON REUTERS
·
Aug 13

Absci Corp reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 13

Absci Corporation Unveils Presentation on AI-Driven Antibody Design and Clinical Pipeline Progress

Reuters
·
Aug 13

Absci Corporation Q2 2025 Results: Revenue Falls to $0.6M, Net Loss Widens to $30.6M

Reuters
·
Aug 13

Absci Q2 EPS $(0.24) Misses $(0.21) Estimate, Sales $593.000K Miss $1.427M Estimate

Benzinga
·
Aug 13

BRIEF-Absci Q2 Operating Income USD -31.393 Million

Reuters
·
Aug 13

Absci Corp - Anticipates Initiation of Phase 1/2a Clinical Trial for Abs-201 in Early 2026

THOMSON REUTERS
·
Aug 13

Absci Corp - NOW Believes Existing Cash, Cash Equivalents, Short-Term Investments Sufficient to Fund Operations Into H1 2028

THOMSON REUTERS
·
Aug 13

Absci Corp expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
Aug 09

Spanish stocks - Factors to watch on Aug 7

Reuters
·
Aug 07

Almirall And Absci Expand AI Drug Creation Collaboration Adding Second Dermatology Target

Reuters
·
Aug 07

Absci Corporation and Almirall Expand AI Drug Discovery Partnership to Target Dermatological Conditions

Reuters
·
Aug 07

Almirall - Absci Eligible for up to $650 Mln in Payments

THOMSON REUTERS
·
Aug 07

Almirall - Selects Second Target Aimed at Dermatological Indications in AI Drug Collaboration

THOMSON REUTERS
·
Aug 07

Chief Innovation Officer Andreas Busch Reports Acquisition of Common Shares in Absci Corporation

Reuters
·
Jul 29